CN1270718C - 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 - Google Patents

表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 Download PDF

Info

Publication number
CN1270718C
CN1270718C CNB998060283A CN99806028A CN1270718C CN 1270718 C CN1270718 C CN 1270718C CN B998060283 A CNB998060283 A CN B998060283A CN 99806028 A CN99806028 A CN 99806028A CN 1270718 C CN1270718 C CN 1270718C
Authority
CN
China
Prior art keywords
hydroxy
steroids
pregnane
treatment
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998060283A
Other languages
English (en)
Chinese (zh)
Other versions
CN1300219A (zh
Inventor
托布乔恩·贝克斯托罗姆
王明德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plum Lin Company
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1300219A publication Critical patent/CN1300219A/zh
Application granted granted Critical
Publication of CN1270718C publication Critical patent/CN1270718C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB998060283A 1998-03-11 1999-03-10 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 Expired - Fee Related CN1270718C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3786998A 1998-03-11 1998-03-11
US09/037869 1998-03-11
US09/037,869 1998-03-11

Publications (2)

Publication Number Publication Date
CN1300219A CN1300219A (zh) 2001-06-20
CN1270718C true CN1270718C (zh) 2006-08-23

Family

ID=21896803

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998060283A Expired - Fee Related CN1270718C (zh) 1998-03-11 1999-03-10 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用

Country Status (9)

Country Link
US (1) US6455516B1 (https=)
EP (1) EP1063999B1 (https=)
JP (1) JP3877961B2 (https=)
CN (1) CN1270718C (https=)
AT (1) ATE307592T1 (https=)
AU (1) AU756001B2 (https=)
CA (1) CA2321728C (https=)
DE (1) DE69927960T2 (https=)
WO (1) WO1999045931A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
CN101076340B (zh) * 2004-11-18 2011-01-12 梅克芳股份公司 Gaba-类固醇拮抗剂及其治疗cns障碍的用途
RU2413516C2 (ru) * 2004-11-18 2011-03-10 Умекрин Аб Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
DK2792681T3 (en) 2006-11-21 2017-01-23 Umecrine Ab Use of Pregnancy and Androstan Steroids in the Preparation of a Pharmaceutical Composition for the Treatment of CNS Disorders.
US20100204192A1 (en) 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
EP2167098B1 (en) * 2007-06-11 2018-09-05 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
US20090048288A1 (en) * 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
RU2012133627A (ru) * 2010-01-14 2014-04-20 Умекрине Муд Аб Фармацевтическая композиция, содержащая 3-бета-гидрокси-5-альфа-прегнан-20-он, с улучшенными свойствами хранения и растворимости
PL2709631T3 (pl) 2011-05-20 2017-07-31 Inserm - Institut National De La Santé Et De La Recherche Médicale Antagoniści receptora cb1
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP2806877B2 (en) * 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
ES2621528T3 (es) 2012-11-28 2017-07-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Derivados de 3-(4’-sustituido)-bencil éter de pregnenolona
AU2013352141B2 (en) * 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
RU2684616C2 (ru) 2014-01-29 2019-04-10 Умекрин Когнишн Аб Стероидное соединение для применения в лечении печеночной энцефалопатии
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) * 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
KR20240157128A (ko) 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
RS67063B1 (sr) * 2017-01-09 2025-08-29 Relmada Therapeutics Inc Injektabilne suspenzije
WO2018147792A1 (en) * 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
WO2018147791A1 (en) * 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
US20210228596A1 (en) * 2017-10-12 2021-07-29 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
JP2021519799A (ja) 2018-04-05 2021-08-12 アサリナ ファーマ エーピーエス 物質離脱障害を治療するためのｇａｂａ−ａアンタゴニスト
KR20240050372A (ko) 2021-09-14 2024-04-18 난징 미노바 파마슈티컬 컴퍼니, 리미티드 수용성 알로프레그나놀론 유도체 및 이의 제조 방법과 용도
US20250387409A1 (en) 2021-11-10 2025-12-25 Umecrine Cognition Ab 3-beta-hydroxy-3-alpha-ethyl steroids for modulation of the alpha-3 subtype of the gabaa receptor
CA3237550A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
NZ298567A (en) * 1994-11-23 2000-01-28 Cocensys Inc Androstane and pregnane derivatives, pharmaceutical compositions and methods of treatment
BR9809376A (pt) * 1997-05-02 2000-07-04 American Home Prod Pregnan-3-ol-20-onas

Also Published As

Publication number Publication date
CA2321728A1 (en) 1999-09-16
EP1063999B1 (en) 2005-10-26
DE69927960D1 (de) 2005-12-01
CA2321728C (en) 2008-12-09
JP2002506034A (ja) 2002-02-26
DE69927960T2 (de) 2006-07-20
CN1300219A (zh) 2001-06-20
ATE307592T1 (de) 2005-11-15
JP3877961B2 (ja) 2007-02-07
AU3329299A (en) 1999-09-27
AU756001B2 (en) 2003-01-02
WO1999045931A1 (en) 1999-09-16
US6455516B1 (en) 2002-09-24
EP1063999A1 (en) 2001-01-03

Similar Documents

Publication Publication Date Title
CN1270718C (zh) 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
US8119619B2 (en) Pregnane steroids and their use in the treatment of CNS disorders
CN103764151A (zh) Cb1受体拮抗剂
US8372824B2 (en) GABA-steroid antagonists and their use for the treatment of CNS disorders
JP2001513800A (ja) 医薬組成物調製のためのピバガビンの使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: UMEK LIN MUDE CO.,LTD.

Free format text: FORMER OWNER: TORBJORAN BAKSTORROM

Effective date: 20090821

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20090821

Address after: Stockholm

Patentee after: Plum Lin company.

Address before: Swedish chicken

Co-patentee before: Wang Mingde

Patentee before: Tobjorn Beckstorom

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060823

Termination date: 20180310